Much of the brain is still a “black box” since the causes and mechanisms of most brain diseases are still unknown. However, one billion people worldwide suffer some type of neurological disease.
95% of drugs under trial for these diseases fail with an average cost of $2.6 billion per drug because of poor measurements to evaluate the drug’s efficacy and disease progression in patients.
Subjective evaluations and measurements and inadequate patient selection are insurmountable barriers for the development of new successful treatments. Powerful computational tools are necessary to get quantified and reproducible results as this is critical for the advancement of science.